Use of Omega-3 Fat Emulsion (Omegaven) in Infants With Parenteral Nutrition Associated Liver Disease
Phase: PHASE4
Conditions: Parenteral Nutrition Associated Liver Disease
Sponsor: Vanderbilt University Medical Center

 Use of Omega-3 Fat Emulsion (Omegaven) in Infants With Parenteral Nutrition Associated Liver Disease  
     
NCT00862446
October 19, 2010

Version 1.0 
October 19, 2010 
Use of Omega-3 Fat Emulsion (Omegaven™) in Infants with 
Parenteral Nutrition Associated Liver Disease 
William F. Walsh, M.D., Principal Investigator 
Vanderbilt Children’s Hospital 
Nashville, TN 3

Version 1.0 
October 19, 2010 
Table of Contents: 
Study Schema 
1.0 
Background 
2.0 
Rationale and Specific Aims 
3.0 
Animal Studies and Previous Human Studies 
4.0 
Inclusion/Exclusion Criteria 
5.0 
Enrollment/Randomization 
6.0 
Study Procedures 
7.0 
Risks of Investigational Agents/Devices (side effects) 
8.0 
Reporting of Adverse Events or Unanticipated Problems involving Risk to 
Participants or Others 
9.0 
Study Withdrawal/Discontinuation 
10.0 Statistical Considerations 
11.0 Privacy/Confidentiality Issues 
12.0 Follow-up and Record Retention 
Appendices 
Appendix A Study Procedure Calendar 

Version 1.0 
October 19, 2010 
1.0 
Background 
Parenteral Nutrition Associated Liver Disease (PNALD) 
Parenteral nutrition (PN) provides intravenous nutritional supplementation for patients unable to absorb 
adequate enteral nutrients secondary to insufficient intestinal length or function. PN contains the 
macronutrient building blocks of the human diet in their most elemental forms (amino acids and dextrose) 
and is commonly administered with a fat emulsion to avoid essential fatty acid deficiency and to provide 
a calorically dense source of non-protein calories. In addition, PN contains the essential micronutrients 
(electrolytes, trace elements, and vitamins) to provide an optimal nutritional regimen. Before the 
development of PN in the late 1960’s, patients with insufficient gastrointestinal absorptive function 
commonly died of starvation and subsequent complications of malnutrition(1, 2). Today, more than 
30,000 patients are permanently dependent on parenteral nutrition for survival. However, PN continues 
to be associated with hepatic injury that occurs at an unpredictable rate and includes both biochemical, 
i.e., elevated serum bilirubin, aminotransferase and alkaline phosphatase, and histologic alterations such
as steatosis, steatohepatitis, lipidosis, cholestasis, fibrosis, and cirrhosis (3, 4). These abnormalities,
which worsen with the duration  of PN administration, is  more prevalent in the pediatric population.
Additional risk factors for this condition include prematurity, low birth weight, long-term use of PN, the
lack of concomitant enteral intake, sepsis, and multiple operative procedures (5).
Although the pathological features of  PNALD have been well described, the etiology, prevention, and 
treatment of this complication are not well understood. Multiple hypotheses exist to explain the 
pathogenesis of PNALD including altered gut hormonal profiles (6), the propensity for bacterial 
translocation in the absence of enteral intake (7, 8), intestinal stasis resulting in the reduced clearance of 
hepatotoxic bile acids (8), and direct deficiencies or toxic components of the PN solution itself resulting in 
excessive glucose calorie uptake, excessive lipid infusion, or nutritional deficiencies such as essential 
fatty acid deficiency (9-11). None of these theories has been confirmed consistently. The etiology of 
PNALD is currently considered multifactorial. Available treatment options for this disease process are 
limited and have achieved moderate success at best. Care of the PN-dependent patient is focused on 
gradually increasing enteral caloric intake as the residual bowel adapts allowing  PN to be discontinued 
(12).  In fact, it has been shown both experimentally and clinically that partial enteral nutrition, when 
tolerated, helps to protect against the development of PNALD (13-15). In severe cases of refractory 
hepatic failure, liver transplantation with or without accompanying small bowel transplantation remains 
the only treatment option.  
Role of Intravenous Fat Emulsion on PN Associated Liver Disease 
Recent evidence demonstrates that lipids are metabolized differently depending on their route of 
administration. Enteral lipids are absorbed by the enterocyte in the small bowel mucosa in the form of a 
micelle and packaged into chylomicrons which are released into the portal venous system for ultimate 
uptake and disposal in the liver. Once in the bloodstream, these particles rapidly acquire apolipoproteins 
from circulating high-density lipoproteins and can subsequently be metabolized by the liver. The 
emulsified particles of commercially made and intravenously administered lipid emulsions, such as 
Intralipid®, mimic the size and structure of chylomicrons, but differ in their content. In contrast to 
chylomicrons, artificial lipid particles primarily contain essential fatty acids and omega-6 triglycerides and 
are devoid of cholesterol or protein. Recent studies suggest that these omega-6 fatty acid-containing 
emulsions are dependent on lipoprotein lipase, apolipoprotein E, and low-density lipoprotein receptors 
for clearance, and are metabolized with less lipolysis and release of essential fatty acids than are 
chylomicrons. In fact, it appears that they may be cleared as whole particles by tissues other than the 
liver.(16) These factors may account for the increased incidence of steatohepatitis associated with the 
intravenous administration of Intralipid®. 
The mechanism of clearance of omega-3 fatty acid containing lipid emulsions is unknown, but appears to 
be largely independent of the pathways identified above (17). Furthermore, omega-3 fatty acid solutions 
have been shown to decrease de novo lipogenesis (18), prevent or attenuate PN-induced 
hepatosteatosis in rats (19) and guinea pigs and ameliorate the severity of high-fat diet-induced 
hepatosteatosis in rats (20). In addition, omega-3 fatty acids can interfere with the arachidonic acid 

Version 1.0 
October 19, 2010 
pathway of inflammation (18, 21). They can displace arachidonic acid from tissue fatty acid pools, 
thereby reducing the availability for eicasanoid-synthesizing enzymes and inflammation (21).  
  
Table 1 summarizes the composition of Intralipid® and Omegaven™ fat emulsions. 
 
Table 1 
Comparison of Parenteral Fat Emulsions (10 grams fat/100 mL) 
OIL 
Intralipid® 
Liposyn® II 
Omegaven™ 
Soybean 
10 
5 
 
Safflower 
 
5 
 
Fish 
 
 
10 
% FATS 
 
 
 
Linoleic 
50 
65 
0.1-0.7 
α-linolenic 
9 
4 
<0.2 
E.P.A. 
 
 
1.3-2.8 
D.H.A. 
 
 
1.4-3.1 
Arachidonic acid 
 
 
0.1 -0.4 
Glycerol 
2.3 
2.5 
2.5 
Egg Phospholipid 
1.2 
1.2 
1.2 
Available in the   United 
States 
Yes 
Yes 
No 
 
                                                                                                                                                  
Rationale for Omegaven™ Treatment 
 
Unlike conventional intravenous fat emulsions, Omegaven™ is comprised solely of fish oils containing 
primarily omega-3 fatty acids. Animal studies have shown that IV fat emulsions such as fish oil that are 
high in eicosapentaenic and docosahexaenoic acid reduce impairment of bile flow as seen in cholestasis 
caused by conventional fat emulsions(19,20). We hypothesize that by administering Omegaven™ in 
place of conventional phytosterol/soybean fat emulsions, that the cholestasis may be reversed and  
patients will be able to be maintained on adequate PN until they are able to ingest adequate nutrition 
enterally. 
 
2.0 
Rationale and Specific Aims 
 
In the United States, patients dependent upon parenteral nutrition (PN) receive parenteral fat emulsions 
composed of soybean oils. Lipids are necessary in PN dependent patients due to their high caloric value 
and essential fatty acid content. They have been implicated in predisposing patients to PN associated 
liver disease. Phytosterols such as those contained in soybean oils are thought to have a deleterious 
effect on biliary secretion.  Accumulation of lipids in the hepatic Kupffer cells may further impair liver 
function. 
 
Children requiring prolonged courses of  PN are at risk for developing PN associated liver disease. We 
hypothesize that although omega-6 fatty acid emulsions prevent fatty acid deficiency, they are not 
cleared in a manner similar to  enteral chylomicrons and therefore accumulate in the liver and resulting in 

Version 1.0 
October 19, 2010 
steatotic liver injury. We  further hypothesize that a fat emulsion comprised of omega-3 fatty acids (i.e., 
fish oil) such as Omegaven™ would be beneficial in the management of steatotic liver injuiry by its 
inhibition of de novo lipogenesis, the reduction of arachidonic acid-derived inflammatory mediators, 
prevention of essential fatty acid deficiency through the presence of small amounts of arachidonic acid, 
and improved clearance of lipids from the serum. Animal studies have shown that IV fat emulsions (IFE)  
such as fish oil that are high in eicosapentaenic and docashexaaenoic acid reduce impairment of bile 
flow which is seen in cholestasis caused by conventional fat emulsions.  Furthermore, we hypothesize 
that that intravenous omega three fatty acids will be well tolerated and might reduce the inflammatory 
effect in the liver of prolonged PN exposure and could potentially reverse any hepatic dysfunction due to 
PN/IFE use.  By administering Omegaven™ in place of conventional phytosterol/soybean fat emulsions 
we may reverse or prevent the progression of PN associated cholestasis and thus allow the patient to be 
maintained on adequate PN until they are able to ingest adequate nutrition enterally. 
 
Assessment of the effect of treatment will be based on a non-randomized, open-labeled, prospective 
study of intravenously administered Omegaven™ fat emulsion to determine safety and preliminary 
efficacy in the treatment of PN associated liver injury. 
 
Specific Aims /Objectives 
 
1. To determine the safety profile of an intravenous omega-3 fat emulsion (Omegaven™) 
 
Hypothesis for Aim 1: 
1.1 – PN containing Omegaven™ will be safe for patients with respect to the risk of unexpected bleeding, 
coagulopathies, and other adverse events. 
1.2 – PN containing Omegaven™ will promote more short-term growth and development than 
conventional fat emulsions. 
1.3-Incidence of sepsis will be similar to historical incidence of sepsis on TPN and IL™ 
  
2. To determine if  established PN associated liver disease can be reversed or its progression halted by 
using a parenteral fat emulsion prepared from fish oil as measured by normalization of serum levels of 
hepatic enzymes and bilirubin. 
 
Hypothesis for Aim 2: 
2.1 – Our primary hypothesis is that, after reaching bilirubin levels > 2.5 mg/dL, patients receiving 
Omegaven™ will reach a bilirubin level ≤ 2 mg/dL faster than patients receiving conventional fat 
emulsions. Additionally, patients receiving Omegaven™ will experience a decrease in their levels of 
bilirubin and other hepatic enzymes over time. 
2.2 – Patients with surgical gastrointestinal disease and cholestasis will improve clinical hepatic status. 
2.3 – Since patients receiving Omegaven™ will have improved immune function, they will have a lower 
infection rate then patients receiving conventional fat emulsions. 
2.4 – Due to a better general hepatic condition, patients receiving Omegaven™ will also experience 
lower occurrence of liver transplant, death from hepatic associated causes, and blood transfusions. 
 
3.0 
Animal Studies and Previous Human Studies 
 
Animal Studies 
 
In initial studies at Children’s Hospital Boston, they hypothesized that the development of PNALD may 
be dependent on both the route and quantity of fat administration and that omega-3 fatty acids would 
prevent or reduce de novo lipogenesis and the subsequent liver injury independent of the route of 
administration. Specifically, they characterized a previously established murine model of PN-associated 
liver injury to investigate whether enteral lipid administration would protect against the development of 
steatohepatitis in PN-dependent animals. This murine model of enteral PN-induced steatohepatitis is 
largely due to a high carbohydrate load and essential fatty acid deficiency. Although this model is not 

Version 1.0 
October 19, 2010 
replicative of the clinical setting, it is a model that maximizes liver steatosis. In this model, mice are 
treated with oral PN for 19 days before being sacrificed. These animals develop severe fatty liver changes 
demonstrated by MRI spectroscopy and histology (H&E, PAS, and oil red O staining), and also have 
biochemical changes consistent with liver injury (elevated alkaline phosphatase and serum 
transaminases). Experimental groups were supplemented with Intralipid® by several routes of 
administration including orally, intravenously, and subcutaneously. Other groups were also supplemented 
with omega-3 fatty acids (Omegaven™) by the same routes of administration.  In this study they found a 
consistent pattern of protection against PN-associated steatohepatitis by administering enteral Intralipid® 
(22). In mice that received the highest dose of enteral Intralipid®, there was a marked decrease in the 
extent of overall liver injury as measured by gross inspection, histologic analysis, liver fat content, and 
serum liver enzyme levels. In all areas of this investigation, mice treated with enteral lipid most closely 
resembled the control mice that did not receive PN as part of the experimental protocol. These results 
were in complete contrast to the extensive fatty infiltration and evidence of hepatic injury found in mice 
that received PN without lipid supplementation as well as in mice that received PN with intravenous 
Intralipid®. Mice receiving intravenous Intralipid® had the most severe liver changes.  Both groups of 
animals developed marked hepatic steatosis with macrovesicular fatty infiltration and significant 
elevations in spectroscopic liver fat content and serum transaminase levels. In addition, the effect of 
enteral Intralipid® supplementation appeared to be dose-dependent; mice receiving one-third the dose of 
enteral Intralipid® showed improved liver histology but still demonstrated a moderate degree of liver 
injury by spectroscopy and serum liver function tests. The nutritional model employed in this study 
provided all experimental mice with enteral PN solution ad libitum. In this way, mice were not force-fed 
PN and self-regulated their PN intake by demands for growth and energy. Importantly, all mice gained 
weight throughout the 19-day protocol, and there were no differences in weight gain parameters between 
the groups. The PN solution was a typical pediatric stock formula mixed at their institution containing 
20% dextrose and 2% amino acids. Each milliliter of this formula provides 0.2 g (0.68 kilocalories) of 
dextrose and 0.02 g (0.08 kilocalories) amino acid. As the daily intake per animal of PN averaged 15 ml, 
mice were ingesting approximately 11.4 kilocalories/day and 456 kilocalories/kg/day. This caloric load is 
similar to the established dietary energy needs of the mouse (23). The parenteral fat source used in this 
study was Intralipid® 20% (Baxter, Deerfield, Illinois), which is a soybean oil-based emulsion. Each 
milliliter of this emulsion contains 0.2 g (2.0 kcal) of fat. They recognized that the model may not 
completely match the clinical, human, setting of intravenous PN-administration; however, their goal was 
to produce a fatty liver with biochemical evidence of injury.  
  
In a second set of experiments, the same murine model was used to determine whether Omegaven™ 
(Fresenius- Kabi, Bad Homburg, Germany), a commercial fish oil fat emulsion available in Europe, 
would prevent fatty liver changes by enteral or parenteral routes of administration, and to determine the 
serum fatty acid profile of these animals. Animals receiving Omegaven™ via the oral and intravenous 
routes had completely normal livers on histology and MRI spectroscopy revealed normal liver fat content. 
Liver functions tests in orally treated animals were also within the norm, while there were minimal 
elevations in intravenously treated groups. There was no fatty acid deficiency in these groups as 
determined by Mead acid (5,8,11-Eicosatrienoic acid) levels in the serum fatty acid analysis. Mead acid is 
the only polyunsaturated fatty acid of note produced de novo by animals and only accumulates under the 
conditions of essential fatty acid deficiency. Furthermore, arachidonic acid levels were low in 
Omegaven™ treated animals consistent with previous reports. In a third set of experiments, mice were 
made severely fatty acid deficient. These mice were treated for 10 days with Omegaven™ and had 
complete reversal of their fatty acid deficiency. 
 
Similarly, other investigators studied livers in a newborn pig model and  showed that intravenous 
administration of fish oil, which consists primarily of omega-3 fatty acids, reduced parenteral nutrition-
induced cholestasis.(22) However, the study was only 3 weeks in duration and long-term effects from 
administration of omega-3 fatty acids alone were not evaluated.  In fact, the idea that one could remove an 
essential fatty acid from the standard regime of nutritional support by PN has not been accepted.  It has 

Version 1.0 
October 19, 2010 
been thought that reduction of an essential fatty acid, such as omega-6, during long-term therapy would 
result in fatty acid deficiency and deterioration of the health of the patient. Our experience to date, as 
discussed below, demonstrates that the use of Omegaven™ as monotherapy does not result in the 
development of essential fatty acid deficiency and it can actually be used to as monotherapy to treat this 
deficiency state.   
Preliminary Safety and Efficacy Data for Use of Omegaven™ in Other Diseases 
Omegaven™ has been used for over 10 years as an adjunct to conventional fat emulsions.  According to 
current data, an increase in the proportion of omega-3 fatty acids is thought to optimize nutrition in 
general, but in particular benefit patients whose underlying disease might benefit from an increase in 
omega-3 fatty acids.  An adequate intake of omega-3 fatty acids results in anti-inflammatory and 
immunomodulatory effects that are protective in nature from inflammatory tissue damage, capillary 
permeability, and improved immunological resistance. It may also reduce the risk of thrombosis and 
increase microvascular perfusion due to its anti-aggregatory and vasodilatory effects. 
In Europe and Asia, the use of parenteral omega-3 fatty acids has been used in the following adult patient 
populations (24-28): 
•
post traumatic and post surgical patients
•
patients experiencing early stages of sepsis/SIRS
•
patients at risk of hyperinflammatory processes
•
patients with inflammatory bowel disease (Crohn’s disease, ulcerative colitis)
•
patients with inflammatory skin diseases (psoriasis, atopic eczema)
The dosing used in these patients was 0.1 g (1ml) to a maximum of 0.2 (2ml) /kg body weight. The 
infusion rate used did not exceed 0.5ml/kg/body weight/hour.  Since it was intended to be infused in 
combination with conventional fat emulsions, the total fat intake was limited to 10-20% as fish oil.  The 
duration of administration did not exceed 4 weeks. 
Preliminary Safety and Efficacy Data for Use of Omegaven™ in Infants 
Pediatric experience with Omegaven™ is limited to 2 unpublished clinical trials.  These trials were 
performed in Germany and Taiwan (29). The German study was a controlled, randomized, open parallel-
group clinical study to investigate whether or not omega-3 fatty acids could be incorporated into the 
plasma phospholipids of very low birth weight preterm infants.  In this 7-day safety trial, Omegaven™ 
use was evaluated on the basis of clinical, laboratory, and antioxidant parameters and lipid metabolism. 
Treatment was started on day 3-5 of life and continued for a total of 7 days. Patients received 
Omegaven™ plus conventional soybean fat emulsion or soybean emulsion alone.  The maximum dose of 
Omegaven™ in the study was 0.2 gm/kg/day.  The study concluded that the Omegaven™ was well 
tolerated in this group of preterm infants in respect to both hematological and biochemical parameters. 
The incidence of reported adverse events between both study groups was similar. The eicosapentaenoic 
acid (EPA) content of plasma phospholipids increased significantly in the Omegaven™ arm, with the 
proportion of EPA to the total fatty acids reaching almost three times the baseline value. The sum of 
omega-3 fatty acids showed a significantly greater increase in the Omegaven™ group compared to the 
conventional treatment arm. 
The Taiwanese study was a single center, controlled, open-labeled study conducted to investigate the 
safety of parenteral administration of Omegaven™ in preterm infants. The group of 20 infants were 
randomized to one of two treatment groups; one consisting of Omegaven™/conventional lipids and the 
other consisting of conventional lipids alone.  The average dose of Omegaven™ in the treatment group of 
this 14-day study was 0.13 + 0.02 g/kg/day.  There were no significant differences between the two 
groups with regard to body weight and length. Similarly, there was no significant difference in the 

Version 1.0 
October 19, 2010 
hematological or biochemical parameters.  There were no adverse events that were attributable to 
Omegaven use. It was concluded that Omegaven™ was well tolerated in these preterm infants. 
 
 
Results of Prior Patient at Children's Hospital, Boston 
 
The only prior use of  Omegaven™ for monotherapy, both in the United States as well as well as abroad,  
is limited to its use in an adolescent male in 2002 at Children’s Hospital Boston, who required a soy free 
form of parenteral fat emulsion for the treatment of essential fatty acid deficiency. In that instance, 
therapy was started at 0.2gm/kg/day and advanced to 0.67 gm/kg/day. He remained on Omegaven™ a 
total of 57 days. His essential fatty acid deficiency corrected and he did not experience any adverse events 
during his course of therapy that could be attributed to the use of Omegaven™(30). 
 
Experience in PN Liver Injury 
 
A single patient with bridging fibrosis due to prolonged parenteral nutrition use has been treated by 
compassionate use with Omegaven at Children's Hospital, Boston (FDA IND #
). By age 6 months, 
this male infant was listed for a liver-small bowel transplant due to severe hepatic disease. His liver 
biopsy showed predominantly centrilobular, hepatocellular damage with ballooning of the hepatocytes, 
cholestasis, local steatosis, focal giant cell transformation, expansion of portal tracks with mild 
inflammation, bile duct proliferation, mild fibrosis, and mild periportal iron deposits. On a subsequent 
biopsy, he progressed to bridging fibrosis.  Omegaven™ was started at a dose of 0.2 g/kg/day IV and 
advanced by 0.2 g/kg/day increments to 1 g/kg/day over a 14-day period. In order to ensure adequate 
caloric intake, additional non-protein calories were provided as parenteral carbohydrates (as dextrose).  
No other parenteral form of fat emulsion was administered during Omegaven™ therapy.  His enteral 
feeds were advanced while on the Omegaven™. Once the goal dose of Omegaven™ was reached, the 
direct bilirubin declined and normalized.  His AST also normalized and he was removed from the liver-
small bowel transplant list. Weekly c-reactive protein (CRP) levels were obtained to monitor systemic 
inflammation. CRP levels decreased from a high of 1.85 to 0.17 mg/dL (Normal <0.5). He continues to 
receive Omegaven™ at a dose 1g/kg/day and has had no evidence of bleeding or clinical evidence of 
essential fatty acid deficiency. His direct bilirubin continues to be within the normal range and he has no 
evidence of jaundice. He is still receiving approximately 50-% of his total caloric needs via the parenteral 
route. He continues to grow and is achieving his developmental milestones appropriately. This child has 
been on Omegaven™ for 27 months. 
 
Since that time, an additional 55  patients have been treated with Omegaven™.  As of August 9, 2007, no 
patient receiving Omegaven™ has died of PN associated liver disease. 
 
 
4.0 
Inclusion/Exclusion Criteria 
 
Inclusion Criteria: 
 
1. Patients aged 0 to 2 years will be PN dependent (unable to meet nutritional needs soley by enteral 
nutrition) and are expected to require PN for at least another 30 days 
2. Patients considered eligible for study participation must have parenteral nutrition associated liver 
disease (PNALD) as defined as a direct bilirubin of >2.5 mg/dl or more. Other causes of liver disease  
should be excluded. A liver biopsy is not necessary for treatment. 
3. Signed patient informed consent. 

Version 1.0 
October 19, 2010 
4. The patient must have utilized standard therapies to prevent the progression of his/her liver disease
including surgical treatment, cyclic PN, avoiding overfeeding, reduction/removal of copper and
manganese from PN, advancement of enteral feeding, and the use of  ursodiol (i..e., Actigall®).
Exclusion Criteria: 
1. Other causes of chronic liver disease (Hepatitis C, Cystic fibrosis, biliary atresia,  and alpha 1 anti-
trypsin deficiency,)
2. Enrollment in any other clinical trial involving an investigational agent (unless approved by the
designated physicians on the multidisciplinary team)
3.. The parent or guardian or child unwilling to provide consent or assent
4. Patients with severe hemorrhagic disorders
5. Patients with severe liver disease not caused by prolonged PN and renal insufficiency
6. Patients with uncontrolled diabetes mellitus
5.0
Enrollment/Randomization 
NICU attendings will screen their patients for infants who need prolonged parenteral nutrition (TPN) and 
have Parenteral Nutrition Associated Liver Disease.  The attending physician will ask the family if they 
would like more information about the study.   Dr. Walsh will be notified of these infants, and assess if 
they are suitable candidates.  Dr. Walsh or the NICU research nurses will explain the study to the infant’s 
parents / legal guardians and obtain informed consent in the NICU at Vanderbilt Children’s Hospital. 
Assessment of the effect of treatment will be based on a non-randomized, open-labeled, prospective 
study of intravenously administered Omegaven™ fat emulsion to determine safety and preliminary 
efficacy in the treatment of PN associated liver injury. 
6.0
Study Procedures 
Omega-3 Fat Emulsion (Omegaven™) 
Bottles containing 50mL or 100 mL of 10% Omegaven™ will be purchased from International Pharmacy 
of Hamburg, Germany or directly from the manufacturer. Approval is pending from the FDA to allow for 
billing of Omegaven.   Omegaven™ is manufactured by Fresenius Kabi AG, Bad Homburg v.d.h, 
Germany. Omegaven™ is formulated as an emulsion from fish oils.  See attached Product Information 
Sheet.  
While inpatient, the emulsion for each patient will be provided in its original container for volumes more 
than 96 ml/day.  Doses less than 96 ml/day will be repacked into syringes to allow for administration via 
syringe pump.  If patients are to be discharged home on Omegaven™, all doses will be administered 
from the original manufacturer’s container. 
All study materials will be stored securely until the time of administration. The bottles will be stored at 
room temperature below 30° C (do not freeze). Damaged or suspect drug will be returned unused to 
Fresenius- Kabi. Containers should be shaken before use. 
All supplies for the study will be accompanied by accountability and shipping documents and will be 
maintained by the Investigator. Information recorded on these accountability and shipping documents will 
include relevant dates, batch numbers, quantities received or dispensed, to whom dispensed, returned 
drug and drug lost or damaged. At the end of the study, all used and unused Omegaven™ will be 
accounted for.  If expired, the remaining drug supplies will be destroyed. 

Version 1.0 
October 19, 2010 
Details of Omegaven™ Administration 
After baseline labs are obtained (Table 2 and 3), therapy with Omegaven™ will be initiated at the goal 
dose of 1 gram /kg/day and is infused over 12-24 hours.  Omegaven™ will be infused intravenously 
through either a central or peripheral catheter alone or in conjunction with parenteral nutrition.   If 
additional fat calories are needed, they will be provided via the enteral route.. The same standards of 
care provided to all patients receiving parenteral nutrition solution will be followed. Routine nutritional 
monitoring is described in Table 3. 
Table 2: Suggested Schedule Safety Monitoring for Omegaven™ Therapy 
(To be done baseline pre-Omegaven™ therapy and weekly until direct bilirubin <0.4 mg/dL) 
Table 3: Suggested Monitoring Schedule for Omegaven™ Therapy 
(Amended  December 26, 2006) 
Parameter 
Baseline 
(pre-
Omegav
en) 
Dail
y 
Q 
week
* 
Periodicall
y*** 
Weight 
X 
X 
Fluid balance 
X 
X 
Vital Signs 
X 
X 
Catheter site/function 
X 
X 
Laboratory test: 
Sodium 
X 
X 
Potassium 
X 
X 
Chloride 
X 
X 
Glucose 
X 
X 
BUN 
X 
X 
Creatinine 
X 
X 
Triglycerides 
X 
X 
Calcium 
X 
X 
Magnesium 
X 
X 
Phosphorus 
X 
X 
Prealbumin 
X 
X 
C reactive protein 
X 
X 
Albumin 
X 
X 
Total protein 
X 
X 
SGPT 
X 
X 
Alkaline phosphatase 
X 
X 
Bilirubin (total and 
direct) 
X 
X 
Parameter 
Baseline 
Biweekly 
Monthly 
Essential Fatty Acid 
Profile  
X 
X 
PT 
X 
X 
PTT 
X 
X 
INR 
X 
X 

Version 1.0 
October 19, 2010 
GGT 
X 
 
X 
 
AST 
X 
 
X 
 
Copper 
 
 
 
X 
Iron 
 
 
 
X 
Vitamins A,D,E 
 
 
 
X 
Essential Fatty Acid 
Profile  
X 
 
X 
 
Free cholesterol 
X 
 
X 
 
Free fatty acids 
X 
 
X 
 
Lipid Panel 
X 
 
X 
 
Hemoglobin 
X 
 
X 
 
Hematocrit 
X 
 
X 
 
RBC 
X 
 
X 
 
WBC 
X 
 
X 
 
Platelets 
X 
 
X 
 
PT 
X 
 
X 
 
PTT 
X 
 
X 
 
INR 
X 
 
X 
 
Fibrinogen 
 
 
 
 
Selenium 
 
 
 
X 
Zinc 
 
 
 
X 
Carnitine 
 
 
 
X 
Aluminum 
 
 
 
X 
Retinol binding 
protein       
(check when getting 
Vit A) 
 
 
 
X 
* More often as necessitated by clinical course; may be reduced in patients who are stable 
and whose biochemical markers have improved. Refer to protocol for additional information 
 
 
In the event that a patient is unable to achieve adequate calories parenterally and is unable to tolerate 
enteral feeds, it may be necessary to evaluate whether or not the patient should continue the study with 
Omegaven™ as monotherapy or resume therapy with conventional fat emulsions so that additional 
parenteral fat calories can be given. The clinical team, in conjunction with the patient's primary physician, 
will determine if the patient should be removed from the protocol. The DSMB will also be notified.   
 
Prior to the administration of each Omegaven™ dose, two nurses will check the dose dispensed against 
the physician’s orders and verify that the infusion pump settings (hourly rate, volume to be infused) are 
correct before the infusion is started. 
 
As previously mentioned, Omegaven™ may be infused in the same manner as conventional fat 
emulsions through either a central or peripheral line. The emulsion is isotonic. It is compatible with 
parenteral nutrition solutions and may be co-infused via y-site. Omegaven™ may be infused through a 
1.2micron inline filter. 
 
 
Dose Modification 
 
Lipid Intolerance 
 
If lipid intolerance develops, defined as serum triglyceride levels > 200 mg/dL, the following will be 
considered prior to reducing the dose: 
 

Version 1.0 
October 19, 2010 
a) If the level was obtained while the patient was receiving a continuous 24- hour infusion of
Omegaven™, the total dose should be infused over 20 hours, and a repeat serum triglyceride level
obtained prior to resuming the infusion 4 hours later.
b) Other sources of lipid intolerance should be considered and addressed (drugs, renal disease)
If the triglycerides continue to remain high despite the aforementioned interventions, a dosage reduction 
of 25% of the current dose will be considered. 
Duration of Therapy 
Patients will remain on Omegaven™ until weaned from PN. Patients may continue monotherapy with 
Omegaven™ as an additional source of calories after the dextrose/protein portion of PN is discontinued 
In the event that a patient who has been listed for a liver or liver/intestinal transplant has an organ 
become available, the participation in this protocol will not preclude them from receiving the transplant. 
Disruption of Therapy 
In event that Omegaven™ cannot be administered (i.e. loss of central venous catheter access, fluid 
restrictions, need to administer an incompatible medication/blood product), the infusion of Omegaven™ 
may be interrupted and resumed when the conflicting situation is resolved. Some potential interventions 
that can be used include:  
Situation 
Possible Solution 
Loss of central venous access 
Administer via peripheral route 
Fluid restriction 
Consult with pharmacy to concentrate PN, 
medications to allow for administration 
Limited access, need to administer 
incompatible medications 
Stop Omegaven™ infusion, flush catheter 
with either NS or dextrose, administer 
incompatible medication, flush catheter, 
resume infusion; may be necessary to 
infuse Omegaven™ over greater than 12 
hours (use multiple syringes so as to keep 
maximum hang time of Omegaven™ 
source container less than 12 hours) 
Discontinuation of Therapy 
Patients will continue to be followed by the PI if in-patient or if discharged they will be followed in the Out-
Patient GI Clinic upon discontinuation of therapy with Omegaven™ for a minimum of 2 months after the 
treatment is stopped.  
Data Collection 
All clinical and laboratory research data will be abstracted from source documents (medical records) and 
recorded and maintained on study specific case report forms (CRF).  These CRFs will be stored within 
individual subject binders in accordance with Good Clinical Practice Standards and FDA requirements. 
Study materials will be kept in the Principal Investigator’s locked office and access will be restricted to 
authorized study staff only.  Subject confidentiality will be maintained by recording subject-specific data 
using a unique confidential study identifier. 
7.0
Risks 

Version 1.0 
October 19, 2010 
Potential Risk of Omegaven™ Treatment 
 
Omegaven has been studied in animal pre-clinical models as well as Phase I, II, III, and post marketing 
human trials in both Europe and Asia. Prolonged bleeding time and an inhibited platelet aggregation can 
occur. It should not be administered to patients known to be allergic to fish or egg protein.  
 
Contraindications to Omegaven™ include the following: 
 
Impaired lipid metabolism 
 
Severe hemorrhagic disorders 
Unstable diabetes mellitus 
Collapse and shock 
Stroke/ Embolism 
Recent cardiac infarction 
 
Undefined coma status 
 
 
Side effects: 
 
The infusion of Omegaven™ can lead to a prolonged bleeding time and an inhibited platelet aggregation. 
In rare cases, patients may experience a fishy taste. 
 
The administration of Omegaven™ should be stopped or reduced if there is a marked increased in blood 
glucose levels during the Omegaven™ infusion. Undesirable effects that are seen during the infusion of 
Omegaven™ that may also occur with conventional fat emulsions (i.e., Intralipid®) include: 
 
Slight rise in body temperature 
 
Heat sensation and/or cold sensation 
Chills 
Flushing or cyanosis 
Lack of appetite, nausea, vomiting 
 
Dyspnea 
Headache, pain in the chest, bone pain 
Priapism 
Increase/decrease blood pressure 
Anaphylactic reactions/erythema 
 
A recent review of the literature suggests a slight change in risk status. There was a single case report of 
an infant developing anemia : J Pediatr. 2010 Feb;156(2):324-6.e1,  Parenteral fish oil-associated burr 
cell anemia. Mallah HS, Brown MR, Rossi TM, Block RC. The mechanisms responsible for formation of 
burr cells are unknown but have been attributed to changes in composition of the lipids of the red blood 
cell membrane. These 
changes affect erythrocyte fragility and ultimately cause shape alterations, which make the red blood 
cells more susceptible to trapping and destruction by the spleen. None of the 13 infants in our study has 
developed any anemia and we will now monitor for that reported complication. 
 
 
Other expected adverse events that are common to all patients with short bowel syndrome, regardless of 
the type of fat emulsion they receive, include blood stream infections and re-admittance to hospital. 
Causes for re-hospitalization include dehydration, bloodstream infections, electrolyte abnormalities, 
bowel obstruction, and central venous catheter malfunction. 
 
Overdose: 
 
In the event of an overdose of Omegaven,™ there is a risk of developing fat overload syndrome that may 
occur when the triglyceride level rises >200 mg/dL acutely as a result of too rapid a rate of infusion, or 
chronically at high infusion rates in associated with a change in the patient’s clinical condition (e.g., renal 

Version 1.0 
October 19, 2010 
dysfunction, sepsis).  In such cases, the infusion should be stopped or, if necessary, continued at a 
reduced dose. Metabolic acidosis has occurred in patients receiving Omegaven™ at excessive doses 
without simultaneous administration of dextrose. 
 
Potential Benefit of Omegaven™ Treatment 
 
Omegaven™ may be effective in stabilizing or reversing hepatic injury associated with the use of 
parenteral nutrition. It may allow the patient to continue to receive the majority of his/her caloric intake 
from parenteral nutrition while advancing on enteral nutrition or awaiting liver or liver/intestinal transplant 
 
 
Potential Risks of No Treatment 
 
Since Omegaven™ will only be offered to those patients for whom no standard therapy is likely to safe 
and effective, the risks of not being treated are those allowing for the natural history of their disease and 
associated clinical manifestations to progress. These include fulminate liver failure and death. 
 
Summary – Overall Risk Assessment 
 
Patients will be at some risk inherent in taking a pharmaceutical agent that has not been fully evaluated 
for long duration treatment. However, the availability of safety data demonstrates no life-threatening risks 
or toxicities to vital organs or physiologic functions. Prolonged bleeding times and inhibition of platelet 
aggregation are a potential risk, especially to those patients with an underlying coagulopathy or those 
being treated with an anticoagulant. The potential benefits of Omegaven™ in this patient population are 
mainly based on the experimental evidence and a single case of dramatic success. However, the study 
will only be available to those for whom no standard therapy is available or appropriate, or has already 
failed. The risks and potential benefits will require careful individual assessment by both the investigators 
and patients.  The heterogeneity of clinical manifestations will lead to non-uniform risk-benefit ratios 
across the eligible patient population. 
 
Potential Benefits 
 
The potential benefits of this study apply directly to the patient in question and to possible improvement 
in the treatment of future patients. If successful, the  experimental treatment will provide a safe and 
effective means of avoiding liver failure requiring transplant or that may  lead to death.  Thus, the 
potenital complications of surgery or fulminant hepatic failure may be avoided.  
 
PN associated liver disease is a life threatening condition . Available therapies (liver/small bowel 
transplant, intestinal lengthening, ursodiol, combination enteral/parenteral feedings) are often 
inadequate.  Phytosterol containing intravenous fat emulsions containing large quantities of omega 6 
fatty acids have been associated with PN associated liver disease. One patient, with bridging fibrosis 
secondary to prolonged PN/lipid therapy, treated with Omegaven™ has had a sustained dramatic 
response with resolution of jaundice and direct bilirubin levels < 2. The safety profile of Omegaven™ has 
been demonstrated to be acceptable for the diseases treated and should be considered as an option for 
patients requiring a form of intravenous fat emulsion. 
 
 
8.0 
Reporting of Adverse Events or Unanticipated Problems involving Risk to Participants 
or Others 
 
Adverse events (AEs) will be assessed and reported from the time of the first Omegaven™ infusion until 
exit from the study. In particular, the patient will be observed during and shortly after Omegaven™ 
administration for the occurrence of anaphylactic or allergic reactions.  Other expected adverse events 
include death, blood stream infection; hemodynamic instability; re-hospitalization for treatment of blood 
stream infection, dehydration, electrolyte abnormalities, catheter malfunctions, bowel obstructions, and 

Version 1.0 
October 19, 2010 
urinary tract infection.  Unexpected adverse events will also be assessed and reported in compliance 
with the VUMC IRB requirements. Patients experiencing any adverse events that are moderate or severe 
in nature and that may be related to Omegaven™ will have their treatment temporarily halted until the 
adverse event has resolved. Dose modifications will occur as described above.If a dose reduction is 
made  for adverse events later considered to be unrelated to Omegaven™, the Omegaven™ dose will 
be increased back to the dose prescribed prior to the dose reduction..  Patients with anaphylactic or 
allergic reactions will not continue Omegaven™ treatment. 
 
Any serious or unsuspected adverse events will be reported to theVUMC IRB and the FDA  within 72 
hours of the occurance being known, or within 24 hours if the event is fatal or life threatening. This will be 
done in person, by telephone, or email,  and by completion of the IRB form for adverse/unexpected event 
reporting. 
 
Adverse events are detected by VCH Neonatology medical and nursing staff during provision of standard 
care services including the routine monitoring of vital signs and daily physical exam data.   Adverse 
events identified by VCH NICU staff are reported to the Principal Investigator immediately by telephone 
or pager, and subsequently to the appropriate board or committee. 
 
The PI, Dr. Walsh, will be responsible for assuring that adverse event reporting requirements are actually 
met. Any patients who have agreed to participate in the trial, but who have not yet undergone 
intervention, will be informed of adverse events. A revised consent document will be submitted to the IRB 
with the adverse event form for review and approval. All adverse events will be classified by the Principal 
Investigator as definitely, probably, possibly, or unrelated to administration of study drug 
 
 
 
9.0 
Study Withdrawal/Discontinuation 
 
Patients will be withdrawn from the study for any of the following: 
 
a) Toxicity considered unacceptable by the  Principal Investigator  
b) Patient/guardian requests to discontinue treatment and/or observation for any reason. 
c)   A suitable organ has been located and the patient is able to undergo a liver or liver/intestinal 
transplant. 
d) Decision by the Principal Investigator that termination is in the patient’s best medical interest. 
 
In the event that a patient is withdrawn from the protocol, study staff will document the date of 
withdrawal, the reason for withdrawal, and the results of all measurements of interest made up to date of 
withdrawal. 
 
 
 
 
 
 
10.0 Statistical Considerations 
 
Analysis of Safety and Tolerability of Omegaven™ 
 
All primary safety and tolerability analyses will be based on descriptive statistics. In secondary analyses, 
we will also assess the statistical significance of differences. Some safety and tolerability outcomes will 
be measured only in the Omegaven™ group. For those, we will compare results before starting PN with 
Omegaven™ (while receiving PN with soybean oil fat emulsions) with after starting PN with 
Omegaven™. The period receiving Omegaven™ will start to be counted 30 days after beginning PN with 
Omegaven™ for the main analysis.  

Version 1.0 
October 19, 2010 
Primary outcomes measured in the Omegaven™ group will include routine measurement of the direct 
bilirubin levels and whether the  INR was ever > 2.   
Primary outcomes measured in the Omegaven™ and soybean based fat emulsion groups will include 
whether triglycerides were ever > 400mg/dL, whether albumin was ever > 3, any occurrence of 
unexpected bleeding and number of times it occurred, occurrence of any anaphylatic reaction, rate of 
blood stream infections as shown by positive blood cultures, rate of line infections and gram positive 
central venous catheter infections..  
 
 
Analysis of Efficacy of Omegaven™ 
 
The primary outcome to gain preliminary evidence of efficacy will be based on the time from baseline to 
normalization of bilirubin level, i.e, first time point among three consecutive in which bilirubin is < 2 
mg/dL. We do not anticipate that any subject will present a rebound on direct bilirubin after normalization. 
However, we will describe the cohort with respect to the frequency of rebounds in bilirubin levels.  
 
Crude comparisons of time to normalize direct bilirubin levels using Omegaven™ Results of these 
analysis will be compared with results of analysis excluding subjects who die or are transplanted. Time to 
reach a total bilirubin of 1.2 will also be compared using survival analysis methods. Analysis of this 
outcome will procede as described for direct bilirubin.   
 
We will also describe individual profiles over time (i.e., 2 months before before baseline or birth until end 
of follow-up period) for all subjects using graphical methods. Trends in liver function markers over time 
will be explored using generalized linear models in which correlations of observations within subjects will 
be accounted using a generalized equations or random effects approach. In these models we will 
hypothesize that for both groups biochemical levels increase for all tests with equal slope before 
treatement. After treatment, however, levels should be decreasing for patients in the Omegaven™ group. 
We will perform these analyses including only subjects who did not die or undergo transplantation and 
including all subjects but assigning for subjects who died or underwent a transplant their worse possible 
outcome after they died or had the transplant. Using descriptive statistics, we will also explore the 
association between spikes in blood tests over time and predictors including transfusions of  red blood 
cell products and blood stream infections.               
 
Assessment of efficacy will be also based on comparison of means (or medians) of the mean and 
maximum modified PELD scores of each subject across all follow-up weeks. Adjustments of these 
comparisons for potential confounders will be based on linear regression models. Mean rates of infection 
will be compared. Liver transplant, mortality, and red blood cell product transfusion events will be 
collected. 
 
 
Limitation of Study 
Biases in our efficacy estimates could also result from misclassification, since the marker of reversal of 
cholestaisis, i.e., direct bilirubin does not accurately translate all components of liver function.  
 
11.0 Privacy/Confidentiality Issues 
 
Study data will be collected on paper Case Report Forms (CRF's) developed by the PI. The CRF can 
only be accessed by valid investigators in the study.  Study participants are only identified in the CRF 
with a sequentially generated study number.  A paper Log with the identifiers of the study subjects will be 
kept in a locked research office and only available for view to the PI, Sub-Investigators, the safety 
monitor if requested and the FDA if requested.   
 
Infants and children enrolled will be assigned a study number that will identify the patient on Case 
Report Forms.  Study numbers will be assigned sequentially with enrollment.  Only the investigators 
involved with the study will have access to the log revealing which patients were assigned which study 

Version 1.0 
October 19, 2010 
numbers.   No identifiable information (such as patient name, medical record number) is included in the 
CRF.  
12.0 Follow-up and Record Retention 
The original copy of the electronic CRF will remain on server for six years after the conclusion of the trial, 
and then destroyed.